Skip to main content
Apyx Medical Corp logo

Apyx Medical Corp — Investor Relations & Filings

Ticker · APYX ISIN · US0323472052 LEI · 5299009QZVYUYO082S45 US Manufacturing
Open in API
Filings indexed 969 across all filing types
Latest filing 2015-08-07 Interim / Quarterly Rep…
Country US United States of America
Listing US APYX

About Apyx Medical Corp

https://apyxmedical.com/

Apyx Medical Corporation is an advanced energy technology company that develops, manufactures, and markets innovative products for surgical and cosmetic markets. The company's proprietary Helium Plasma Platform, which is the foundation for its Renuvion® and J-Plasma® brands, utilizes a unique combination of helium plasma and radiofrequency (RF) energy. These systems are designed to deliver controlled energy for the cutting, coagulation, and ablation of soft tissue, with a primary focus on aesthetic procedures for skin tightening and body contouring. Apyx Medical, formerly Bovie Medical, leverages its expertise in energy-based waveforms to provide transformative solutions for surgeons and their patients.

Recent filings

Filing Released Lang Actions
FORM 10-Q
Interim / Quarterly Report Q2 2015
2015-08-07 English
BOVIE 8-K RE: EARNINGS RELEASE
Earnings Release Classification · 95% confidence The document is a Form 8-K filing dated August 6, 2015, reporting the results of operations for the second quarter ended June 30, 2015. It states that a press release with financial results is attached as Exhibit 99.1. The document itself is short (2481 characters) and primarily serves to announce the earnings release rather than containing detailed financial statements or analysis. According to the 'Menu vs Meal' rule, such a short document announcing a report is classified as an Earnings Release (ER) because it is the initial announcement of quarterly financial results with key highlights. The presence of a press release attached confirms this classification. Therefore, the filing type is Earnings Release (ER) with high confidence.
2015-08-06 English
BOVIE 8-K (07.16.15)
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated July 16, 2015, for Bovie Medical Corporation. The content focuses on the submission of matters to a vote of security holders at the company's annual meeting, including election of directors, approval of a share incentive plan, ratification of the independent auditor, and advisory vote on executive compensation. It provides detailed voting results for each proposal. This matches the description of a Declaration of Voting Results & Voting Rights Announcements (DVA) filing, which reports official results from shareholder votes at general meetings. The document is not an announcement of a report, nor is it a full annual report or other financial report. Therefore, the correct classification is DVA with high confidence.
2015-07-17 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 9, 2015, reporting the resignation of the Chief Financial Officer and the appointment of an interim CFO. The content focuses on changes in senior management positions, including details about the new interim CFO's background and compensation arrangements to be disclosed later. There are no financial statements or earnings data presented, nor is this a report of voting results or a regulatory compliance filing unrelated to management changes. The primary subject is the change in the company's board or senior management. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 4256 characters, which is consistent with a typical 8-K filing for management changes.
2015-06-15 English
DEF 14A
Proxy Solicitation & Information Statement
2015-05-29 English
FORM SD
Regulatory Filings Classification · 95% confidence The document is a Form SD filed with the SEC, titled 'Specialized Disclosure Report,' specifically concerning Conflict Minerals Disclosure for the calendar year 2014. It references Rule 13p-1 under the Securities Exchange Act, which mandates disclosure about the origin of certain minerals used in products. The document includes a detailed explanation of the company's inquiry and findings regarding conflict minerals, and it is signed by the CEO. The length is 4182 characters, which is relatively short but contains substantive disclosure information specific to conflict minerals, a specialized regulatory filing. Form SD is a specialized disclosure report and does not fall under Annual Report (10-K), Interim Report (IR), or other financial reports. It is a regulatory filing specific to conflict minerals disclosure requirements. Therefore, the appropriate classification is Regulatory Filings (RNS).
2015-05-29 English

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.